{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:33:52Z","timestamp":1794627232566,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H05051"],"award-info":[{"award-number":["JP21H05051"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H00563"],"award-info":[{"award-number":["JP20H00563"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"MEXT | Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJFR205J"],"award-info":[{"award-number":["JPMJFR205J"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01422-6","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T17:55:29Z","timestamp":1764698129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1079-6888","authenticated-orcid":false,"given":"Ami","family":"Inokuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haryoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-5131","authenticated-orcid":false,"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3042-329X","authenticated-orcid":false,"given":"Shoko","family":"Ukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8263-9902","authenticated-orcid":false,"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"1422_CR1","volume-title":"WHO classification of tumours: haematolymphoid tumours","author":"WHO classification of Tumours Editorial Board","year":"2024","unstructured":"WHO classification of Tumours Editorial Board WHO classification of tumours: haematolymphoid tumours. 5th edn. Lyon, France: International Agency for Research on Cancer; 2024.","edition":"5th edn"},{"key":"1422_CR2","first-page":"1741","volume":"18","author":"MH Ellman","year":"1991","unstructured":"Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991;18:1741\u20133.","journal-title":"J Rheumatol"},{"key":"1422_CR3","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"K Ekstr\u00f6m Smedby","year":"2008","unstructured":"Ekstr\u00f6m Smedby K, Vajdic CM, Falster M, Engels EA, Mart\u00ednez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029\u201338.","journal-title":"Blood"},{"key":"1422_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2141.2011.08606.x","volume":"153","author":"N Watanabe","year":"2011","unstructured":"Watanabe N, Noh JY, Narimatsu H, Takeuchi K, Yamaguchi T, Kameyama K, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto\u2019s disease. Br J Haematol. 2011;153:236\u201343.","journal-title":"Br J Haematol"},{"key":"1422_CR5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO.2005.04.6227","volume":"24","author":"TR Mikuls","year":"2006","unstructured":"Mikuls TR, Endo JO, Puumala SE, Aoun PA, Black NA, O\u2019Dell JR, et al. Prospective study of survival outcomes in Non-Hodgkin\u2019s lymphoma patients with rheumatoid arthritis. J Clin Oncol. 2006;24:1597\u2013602.","journal-title":"J Clin Oncol"},{"key":"1422_CR6","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1200\/JCO.2010.29.2243","volume":"28","author":"O Landgren","year":"2010","unstructured":"Landgren O, Pfeiffer RM, Kristinsson SY, Bjorkholm M. Survival patterns in patients with Hodgkin\u2019s lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol. 2010;28:5081\u20137.","journal-title":"J Clin Oncol"},{"key":"1422_CR7","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/ijc.27944","volume":"132","author":"JF Simard","year":"2013","unstructured":"Simard JF, Baecklund F, Chang ET, Baecklund E, Hjalgrim H, Olov Adami H, et al. Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes. Int J Cancer. 2013;132:2659\u201366.","journal-title":"Int J Cancer"},{"key":"1422_CR8","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","volume":"25","author":"M Fallah","year":"2014","unstructured":"Fallah M, Liu X, Ji J, F\u00f6rsti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol. 2014;25:2025\u201330.","journal-title":"Ann Oncol"},{"key":"1422_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0105-4","volume":"8","author":"G Kleinstern","year":"2018","unstructured":"Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, et al. History of autoimmune conditions and lymphoma prognosis. Blood Cancer J. 2018;8:73.","journal-title":"Blood Cancer J"},{"key":"1422_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102647","volume":"121","author":"JS Kim","year":"2021","unstructured":"Kim JS, Kim IH, Byun JM, Chang JH. Population-based study on the association between autoimmune disease and lymphoma: national health insurance service-national sample cohort 2002-2015 in Korea. J Autoimmun. 2021;121:102647.","journal-title":"J Autoimmun"},{"key":"1422_CR11","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.clml.2017.11.009","volume":"18","author":"JL Koff","year":"2018","unstructured":"Koff JL, Rai A, Flowers CR. Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER-medicare cohort. Clin Lymphoma Myeloma Leuk. 2018;18:e115\u2013e21.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1422_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00296-002-0229-4","volume":"22","author":"L Varoczy","year":"2002","unstructured":"Varoczy L, Gergely L, Zeher M, Szegedi G, Illes A. Malignant lymphoma-associated autoimmune diseases\u2013a descriptive epidemiological study. Rheumatol Int. 2002;22:233\u20137.","journal-title":"Rheumatol Int"},{"key":"1422_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/art.22579","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56:1433\u20139.","journal-title":"Arthritis Rheum"},{"key":"1422_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017;76:497\u2013503.","journal-title":"Ann Rheum Dis"},{"key":"1422_CR15","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1111\/cas.15894","volume":"114","author":"K Tanaka","year":"2023","unstructured":"Tanaka K, Ichikawa A, Umezawa N, Yamamoto K, Yoshifuji K, Okada K, et al. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023;114:3719\u201327.","journal-title":"Cancer Sci"},{"key":"1422_CR16","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679\u201386.","journal-title":"JAMA"},{"key":"1422_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-immunol-101619-031510","volume":"38","author":"N Ghilardi","year":"2020","unstructured":"Ghilardi N, Pappu R, Arron JR, Chan AC. 30 years of biotherapeutics development-what have we learned? Annu Rev Immunol. 2020;38:249\u201387.","journal-title":"Annu Rev Immunol"},{"key":"1422_CR18","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"1422_CR19","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355.","journal-title":"N Engl J Med"},{"key":"1422_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117\u201328.","journal-title":"N Engl J Med"},{"key":"1422_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"1422_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15\u201329.","journal-title":"Ann Rheum Dis"},{"key":"1422_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450\u201361.","journal-title":"Gastroenterology"},{"key":"1422_CR24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"1422_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059\u201367.","journal-title":"Ann Rheum Dis"},{"key":"1422_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jdv.19520","volume":"38","author":"K Kridin","year":"2024","unstructured":"Kridin K, Abdelghaffar M, Mruwat N, Ludwig RJ, Tha\u00e7i D. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study. J Eur Acad Dermatol Venereol. 2024;38:315\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1422_CR27","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/jamia\/ocae094","volume":"31","author":"Y Kawakami","year":"2024","unstructured":"Kawakami Y, Matsuda T, Hidaka N, Tanaka M, Kimura E. Toward a unified understanding of drug-drug interactions: mapping Japanese drug codes to RxNorm concepts. J Am Med Inf Assoc. 2024;31:1561\u20138.","journal-title":"J Am Med Inf Assoc"},{"key":"1422_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2188\/jea.JE20210513","volume":"33","author":"H Fukuda","year":"2023","unstructured":"Fukuda H, Ishiguro C, Ono R, Kiyohara K. The longevity improvement & fair evidence (LIFE) study: overview of the study design and baseline participant profile. J Epidemiol. 2023;33:428\u201337.","journal-title":"J Epidemiol"},{"key":"1422_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/ard.2005.044784","volume":"65","author":"J Franklin","year":"2006","unstructured":"Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis. 2006;65:617\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1422_CR30","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","volume":"99","author":"X Mariette","year":"2002","unstructured":"Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909\u201315.","journal-title":"Blood"},{"key":"1422_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, Lopez-Guillermo A, et al. Follicular lymphoma. Nat Rev Dis Prim. 2019;5:83.","journal-title":"Nat Rev Dis Prim"},{"key":"1422_CR32","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/archinternmed.2008.4","volume":"168","author":"J Koshiol","year":"2008","unstructured":"Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia. Arch Intern Med. 2008;168:1903\u20139.","journal-title":"Arch Intern Med"},{"key":"1422_CR33","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","volume":"126","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194\u2013201.","journal-title":"J Invest Dermatol"},{"key":"1422_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/annonc\/mdu144","volume":"25","author":"M Fallah","year":"2014","unstructured":"Fallah M, Liu X, Ji J, Forsti A, Sundquist K, Hemminki K. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol. 2014;25:1397\u2013404.","journal-title":"Ann Oncol"},{"key":"1422_CR35","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(24)02151-2","volume":"404","author":"MD Russell","year":"2024","unstructured":"Russell MD, Galloway JB. Driving down the cost of biologics: lessons from a nationalised health-care system. Lancet. 2024;404:1723\u20134.","journal-title":"Lancet"},{"key":"1422_CR36","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1422_CR37","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1111\/cas.15926","volume":"114","author":"Y Usui","year":"2023","unstructured":"Usui Y, Ito H, Katanoda K, Matsuda T, Maeda Y, Matsuo K. Trends in non-Hodgkin lymphoma mortality rate in Japan and the United States: a population-based study. Cancer Sci. 2023;114:4073\u201380.","journal-title":"Cancer Sci"},{"key":"1422_CR38","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692\u2013701.","journal-title":"Arthritis Rheum"},{"key":"1422_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0049-0172(92)90009-3","volume":"21","author":"G Russell","year":"1992","unstructured":"Russell G, Graveley R, Seid J, al-Humidan AK, Skjodt H. Mechanisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum. 1992;21:16\u201322.","journal-title":"Semin Arthritis Rheum"},{"key":"1422_CR40","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood.2023020075","volume":"142","author":"JE Amengual","year":"2023","unstructured":"Amengual JE, Pro B. How i treat posttransplant lymphoproliferative disorder. Blood. 2023;142:1426\u201337.","journal-title":"Blood"},{"key":"1422_CR41","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/exd.14647","volume":"31","author":"S Scott","year":"2022","unstructured":"Scott S, Shireen GR, Rachel F, Kirsner RS, Maderal AD. Malignancy risk of non-biologic immunosuppressive therapies: A review of the literature with evidence-based treatment recommendations. Exp Dermatol. 2022;31:1656\u201364.","journal-title":"Exp Dermatol"},{"key":"1422_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109704","volume":"122","author":"H Jiang","year":"2020","unstructured":"Jiang H, Gao H, Wang Q, Wang M, Wu B. Molecular mechanisms and clinical application of iguratimod: a review. Biomed Pharmacother. 2020;122:109704.","journal-title":"Biomed Pharmacother"},{"key":"1422_CR43","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.2169\/internalmedicine.0875-18","volume":"57","author":"M Hagihara","year":"2018","unstructured":"Hagihara M, Mese T, Ohara S, Hua J, Ide S, Inoue M. Methotrexate-associated intravascular large B-cell lymphoma in a patient with rheumatoid arthritis: a very rare case. Intern Med. 2018;57:3001\u20135.","journal-title":"Intern Med"},{"key":"1422_CR44","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00277-021-04645-2","volume":"100","author":"H Nagata","year":"2021","unstructured":"Nagata H, Kuriyama K, Nishikawa R, Ohshiro M, Yamamoto-Sugitani M, Fujimoto-Hirakawa Y, et al. Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder. Ann Hematol. 2021;100:2849\u201350.","journal-title":"Ann Hematol"},{"key":"1422_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/aje\/kwab119","volume":"191","author":"R Sharma","year":"2022","unstructured":"Sharma R, Verna EC, Simon TG, S\u00f6derling J, Hagstr\u00f6m H, Green PHR, et al. Cancer risk in patients with autoimmune hepatitis: a nationwide population-based cohort study with histopathology. Am J Epidemiol. 2022;191:298\u2013319.","journal-title":"Am J Epidemiol"},{"key":"1422_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24324-0","volume":"12","author":"S Lee","year":"2022","unstructured":"Lee S, Kang S, Eun Y, Kim H, Lee J, Koh EM, et al. Increased risk of malignancy in patients with Takayasu\u2019s arteritis: a population-based cohort study in Korea. Sci Rep. 2022;12:22047.","journal-title":"Sci Rep"},{"key":"1422_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.semarthrit.2015.10.003","volume":"45","author":"K Hofheinz","year":"2016","unstructured":"Hofheinz K, Schett G, Manger B. Adult onset Still\u2019s disease associated with malignancy-cause or coincidence? Semin Arthritis Rheum. 2016;45:621\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"1422_CR48","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017;76:2025\u201330.","journal-title":"Ann Rheum Dis"},{"key":"1422_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.1975.03240140031020","volume":"231","author":"JE Lergier","year":"1975","unstructured":"Lergier JE, Gowans JD. Monoclonal IgM immunoglobulinemia in psoriatic arthritis. JAMA. 1975;231:171\u20133.","journal-title":"JAMA"},{"key":"1422_CR50","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/1346-8138.17554","volume":"52","author":"H Sakai","year":"2025","unstructured":"Sakai H, Minami-Hori M, Kuwahara S. Malignancies in patients with psoriasis during and after biological therapy: a single-center experience. J Dermatol. 2025;52:383\u20136.","journal-title":"J Dermatol"},{"key":"1422_CR51","first-page":"271","volume":"15","author":"C Fozza","year":"2005","unstructured":"Fozza C, Dore F, Bonfigli S, Podda L, Longinotti M. Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia. Eur J Dermatol. 2005;15:271\u20133.","journal-title":"Eur J Dermatol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01422-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01422-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01422-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:03:50Z","timestamp":1768165430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01422-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1422"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01422-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS received honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Janssen Pharmaceutical, Kyowa Kirin, Nippon Shinyaku, and Novartis Pharmaceutical. EM received honoraria from Novartis Pharmaceutical, Bristol Myers Squibb, AbbVie, AstraZeneca, Pfizer, Takeda Pharmaceutical, Janssen Pharmaceutical, and Chugai Pharmaceutical. EM received consulting fees from Novartis Pharmaceutical. YKogure received honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, Nippon Shinyaku, and Kyowa Kirin. YKaneko received honoraria from AbbVie, Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Ayumi Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Glaxo SmithKline, Janssen Pharmaceutical, Mitsubishi-Tanabe Pharma, Novartis Pharmaceutical, Pfizer, Sanofi, Taisho Pharmaceutical, and UCB. YKaneko received grants from Asahi Kasei Pharma, Chugai Pharmaceutical, Eisai, Gilead Sciences, Mitsubishi-Tanabe Pharma, and Taisho Pharmaceutical. YKaneko received consulting fees from AbbVie, Asahi Kasei Pharma, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Pfizer, Taisho Pharmaceutical, and UCB. KK received honoraria from Ono Pharmaceutical, Eisai, Astellas Pharma, Novartis Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Sumitomo Pharma, Kyowa Kirin, Janssen Pharmaceutical, MSD, Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol Myers Squibb, Pfizer, Nippon Shinyaku, Daiichi Sankyo, Alexion Pharmaceuticals, AbbVie, Meiji Seika Pharma, Sanofi, Sysmex, Mundipharma, Incyte Corporation, Kyorin Pharmaceutical, PharmaEssentia Japan, Gilead Sciences, Kowa, Amgen, Nippon Kayaku, Asahi Kasei Pharma, and the Chemo-Sero-Therapeutic Research Institute. KK received research support from Chordia Therapeutics, Chugai Pharmaceutical, Takeda Pharmaceutical, and Meiji Seika Pharma. KK received scholarships from Asahi Kasei Pharma, Eisai, Otsuka Pharmaceutical, Kyowa Kirin, Shionogi, Daiichi Sankyo, Takeda Pharmaceutical, Sumitomo Pharma, Chugai Pharmaceutical, Teijin Pharma, Japan Blood Products Organization, JCR Pharmaceuticals, and Nippon Shinyaku. KK owns stock in Asahi Genomics. KK received consulting fees from Meiji Seika Pharma and Otsuka Pharmaceutical. KK has a patent for genetic alterations as a biomarker in T-cell lymphomas and a patent for PD-L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Kyushu University Institutional Review Board for Clinical Research (approval no. 22114-05) and the Keio University Institutional Review Board (approval no. 20236140). Participant consent was obtained through an opt-out procedure, and the requirement for individual informed consent was waived because only anonymized data were used. All methods were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"11"}}